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Multiple reaction monitoring (MRM) mass spectrometry
coupled with stable isotope dilution (SID) and liquid chro-
matography (LC) is increasingly used in biological and
clinical studies for precise and reproducible quantification
of peptides and proteins in complex sample matrices. Ro-
bust LC-SID-MRM-MS-based assays that can be replicated
across laboratories and ultimately in clinical laboratory set-
tings require standardized protocols to demonstrate that
the analysis platforms are performing adequately. We de-
veloped a system suitability protocol (SSP), which employs
a predigested mixture of six proteins, to facilitate perform-
ance evaluation of LC-SID-MRM-MS instrument platforms,
configured with nanoflow-LC systems interfaced to triple
quadrupole mass spectrometers. The SSP was designed
for use with low multiplex analyses as well as high multi-
plex approaches when software-driven scheduling of data
acquisition is required. Performance was assessed by
monitoring of a range of chromatographic and mass spec-
trometric metrics including peak width, chromatographic
resolution, peak capacity, and the variability in peak area
and analyte retention time (RT) stability. The SSP, which
was evaluated in 11 laboratories on a total of 15 different
instruments, enabled early diagnoses of LC and MS anom-
alies that indicated suboptimal LC-MRM-MS performance.
The observed range in variation of each of the metrics
scrutinized serves to define the criteria for optimized LC-
SID-MRM-MS platforms for routine use, with pass/fail cri-
teria for system suitability performance measures defined
as peak area coefficient of variation <0.15, peak width co-
efficient of variation <0.15, standard deviation of RT <0.15
min (9 s), and the RT drift <0.5min (30 s). The deleterious
effect of a marginally performing LC-SID-MRM-MS system
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on the limit of quantification (LOQ) in targeted quantitative
assays illustrates the use and need for a SSP to establish
robust and reliable system performance. Use of a SSP helps
to ensure that analyte quantification measurements can be
replicated with good precision within and across multiple
laboratories and should facilitate more widespread use of
MRM-MS technology by the basic biomedical and clinical
laboratory research communities. Molecular & Cellular
Proteomics 12: 10.1074/mcp.M112.027078, 2623–2639,
2013.
Targeted analysis by liquid chromatography-stable isotope
dilution-multiple reaction monitoring-MS (LC-SID-MRM-MS)1
(also referred to as LC-SID-SRM-MS) has experienced rapid
expansion over the last several years for precise relative
quantification of peptides in the context of basic biological
studies (1–4) and for verification of candidate biomarkers in
clinical applications (5–10). As a quantitative proteomics tool,
LC-SID-MRM-MS offers numerous benefits. First, the overall
precision of analyte quantification, taking into account all
sample processing steps from digestion through data acqui-
sition, is often in the range of 5–10% (CV) above the limit of
quantification (LOQ) and 25% at the LOQ when stable iso-
tope labeled internal standards are employed. The excellent
precision is inherent to LC-SID-MRM-MS experimental de-
sign and how data are acquired. For example, these assays
employ classical SID methodology in which synthetic peptide
standards incorporating one or more labeled amino acids
(13C, 15N or a combination thereof) are spiked at known
amounts into the samples thereby enabling the endogenous
peptide concentration to be determined (1–3). Confidence in
detection and quantification of analytes in SID-MRM-MS is
based on multiple orthogonal measurements, specifically (1)
the labeled internal standard and analyte must co-elute chro-
matographically, (2) the heavy and light peptides fragment
identically (yielding fragment ions that either have identical
m/z values or are shifted upward in mass if they contain the
label), and (3) the fragment ions have the same relative abun-
dance in both the analyte and internal standard channels.
Second, analyte detection sensitivities on the order of ELISA
assays (low ng/ml) are achievable when either sample frac-
tionation or stable isotope standards with capture by antipep-
tide antibodies (SISCAPA) are incorporated into the assay (5,
11–13). Finally, several hundred analytes can be multiplexed
into a single LC-SID-MRM-MS experiment using scheduling
software that segregates collection of data from subsets of
the analyte peptides into different time periods in an LC-
MRM-MS analysis (10, 14, 15). This feature enables imple-
mentation of extremely efficient and high throughput quanti-
tative protein assays. Accordingly, these attributes make
quantitative LC-SID-MRM-MS workflows attractive for adap-
tation into a clinical setting (16, 17). However, before clinical
adoption becomes a reality, robust procedures must be in
place to ensure that optimal performance of an LC-SID-
MRM-MS instrument platform is maintained throughout the
progression of a particular assay (18).
To date, little work has been presented on the development
of standardized protocols that quantitatively assess the “suit-
ability” (19) of nanoflow (typically 150–300 nL/min) high per-
formance liquid chromatography (HPLC) systems interfaced
to triple quadrupole mass spectrometers during the course of
an LC-SID-MRM-MS protein assay. Although promising LC-
SID-MRM-MS biomarker verification studies were recently
reported for cardiovascular disease (8), cancer (7, 10), and
other disorders (9), this approach is still in its infancy. Devel-
opment of quantitative protein/peptide LC-SID-MRM-MS ex-
periments is challenged by many of the same hurdles as those
for small molecules and as this technology evolves, other
unique issues relevant to separation and quantification of
peptides are being realized (20). In the most systematic and
thorough interlaboratory evaluation of LC-SID-MRM-MS to
date, eight laboratories followed a standard operating proce-
dure (SOP) and analyzed identical sample sets to determine
the limits of quantification and measures of variation using a
set of 10 tryptic peptides generated from seven proteins
spiked into human plasma at known concentrations (21). The
results from this study detailed the range of reproducibility
attainable for individual laboratories performing an identical
experimental protocol, based on increasing complexity of the
sample workflow (21). Although the focus of this study was on
the contributions of sample handling and processing to the
intra- and interlaboratory precision (CV) of the measurements,
it also uncovered several common issues that contributed to
intralaboratory variability. Most notably, HPLC-related prob-
lems resulting in peak tailing or random peak shape deformities
caused inconsistencies in peak area integration and subse-
quent quantitative calculations. These performance degrada-
tions often went unnoticed by the laboratory that generated the
data, and were only discovered when all of the data were
evaluated by a small team of expert analysts. In addition, this
study confirmed that use of stable isotope labeled peptides as
internal standards for each peptide analyte helps to dampen
measurement imprecision introduced by HPLC and MS-asso-
ciated problems, but did not eliminate them, nor did it improve
interlaboratory accuracy (22).
Recently, measures have been proposed to quantitatively
monitor aspects of discovery-based proteomics approaches
to better understand technical variability associated with
chromatography, dynamic sampling, ion source configura-
tion, signal intensity of MS and MS/MS scans, and peptide
identification for data-dependent HPLC-MS/MS acquisitions
(23–26). Likewise, there is a critical need for standardized
methods to demonstrate that LC-SID-MRM-MS analysis plat-
1 The abbreviations used are: LC-SID-MRM-MS, Liquid chroma-
tography-stable isotope dilution-multiple reaction monitoring-MS;
CV, coefficient of variation; LOQ, limit of quantification; SSP, system
suitability protocol; FWHM, full width half maximal; RT, retention time.
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forms are performing optimally. However, the approaches
developed for discovery LC-MS/MS platform evaluation are
not directly adaptable to LC-SID-MRM-MS systems, which
have their own unique requirements for system performance
assessment. In this context, we now describe the develop-
ment and evaluation of an easy to implement system suitabil-
ity protocol (SSP) to assess performance metrics of triple
quadrupole-based nanoLC-SID-MRM-MS instrument config-
urations. In this investigation, 11 laboratories comprising 15
individual nanoLC-SID-MRM-MS platforms (from 4 different
vendors, including 8 different models of mass spectrometers)
participated in development and evaluation of an SSP, includ-
ing peptide selection and platform-specific LC and MRM-MS
optimization. Specific chromatographic and MS metrics in-
cluding peak width, chromatographic resolution, peak capac-
ity and the variability in peak area and retention time stability
were monitored to assess reproducibility of replicate injec-
tions of a commercially available peptide mixture generated
from trypsin digestion of 6 bovine proteins. Our study dem-
onstrates that the SSP facilitated rapid detection, diagnosis
and correction of system problems that were a source of
performance degradation in terms of precision (CVs) and sen-
sitivity (limits of detection and quantification, LOD/LOQ). A
critical part of the study involved optimization and use of
vendor-neutral data analysis tools, including Skyline (27), for
rapid assessment of reproducibility and data quality in indi-
vidual laboratories. These tools were then implemented
across multiple sites for comparison of variability among dif-
ferent platform configurations. The SSP was also shown to be
of value in understanding sources of variation across multiple
laboratories performing an identical experimental protocol as
well as for tracking an individual instrument over an extended
period of time. The effect of a marginally performing LC-SID-
MRM-MS system on assay sensitivity, determined by calcu-
lating LOQ values for peptide targets, is illustrated and ap-
propriate limits for all system suitability parameters monitored
are proposed.
MATERIALS AND METHODS
Materials—An equimolar predigested “Bovine 6 Protein Mix” (P/N
PTD/00001/63) was purchased from Bruker-Michrom, Inc. (Auburn,
CA). ReproSil-Pur C18-AQ resin (3 m particle size) was purchased
from Dr. Maisch, GmbH (Ammerbuch-Entringen, Germany). Picofrit
self-pack columns, 75 m ID, 10 m ID tip, were purchased from New
Objective (Woburn, MA).
Study Samples and Sample Preparation—The commercial “Bovine
6 Protein Mix” referred to as 6ProteinMix-QC is a trypsin predigested
mixture containing beta lactoglobulin, lactoperoxidase, carbonic an-
hydrase, glutamate dehydrogenase, alpha casein, and serum albumin
with each protein at an equimolar amount of 100 pmol per commer-
cial vial (iodoacetic acid was used by the vendor to alkylate cysteine
residues). The 6ProteinMix-QC aliquots were centrally prepared at
Vanderbilt University by generating stock solutions with concentra-
tions of 1 pmol/l per protein using an aqueous solution of 30%
acetonitrile (v/v) and 0.1% formic acid (v/v) for dissolution. The stock
solutions were stored as 10 l aliquots (at 1 pmol/l concentration) at
80 °C, and shipped frozen on dry ice to the participating laborato-
ries. As described in detail in the SOP (see supplementary Methods),
before analysis individual sites further diluted the stock solution to a
working solution of 50 fmol/l using an aqueous diluent containing
3% acetonitrile (v/v) and 0.1% formic acid (v/v).
MRM Assay Method Development - Skyline—MRM-MS transition
lists were developed that could be applied to all 15 participating triple
quadrupole mass spectrometers spanning four different vendors (AB
Sciex, ThermoFisher Scientific, Waters and Agilent, for details see
below). The selection of MRM transitions for each peptide was per-
formed independently for each platform and aided by the use of
Skyline software. Skyline was used to build spectral libraries from
data dependent acquisitions and peptide search engine results using
the BiblioSpec library builder (28) so that MRM transitions could be
selected based on previously acquired discovery platform data (for
AB Sciex and Waters instruments). Alternatively (for Thermo and
Agilent instruments), SRM Refinement approaches (29) were used on
a triple quadrupole MS to determine optimal MRM transitions for each
peptide.
To select the five best transitions per peptide, spectral libraries for
different instrument platform data formats were generated in Skyline,
such as an “ABI spectral library” (obtained by data acquisition of the
6 ProteinMix-QC in data dependent IDA mode on a 4000 QTRAP),
and a “Waters spectral library” (obtained by data acquisition of the 6
ProteinMix-QC in data dependent mode on a Waters QTOF Premier).
For the QTRAP 5500 all transitions were selected to be below m/z
1,250 due to the instrument’s upper mass limit of m/z 1250 in Q1 and
Q3. For the ThermoFisher Scientific and Agilent platforms, optimal
peptides and their corresponding transitions were determined by
predicting all tryptic peptides from the 6 ProteinMix-QC and by mon-
itoring all y-ions from y3 to yn-1 on the triple quadrupole TSQ Quan-
tum-Ultra and Agilent 6460 (29). The raw data were imported into
Skyline and results were refined to select the 5 most abundant tran-
sitions for all detectable peptides. From this refined peptide list, 22
peptides that were readily detectable between all MS platforms were
selected for the final MS method. One peptide was included with an
additional charge state, resulting in a total of 115 transitions.
The final list of 22 bovine 6 Protein Mix signature peptides is listed
in the SOP (see supplementary Methods). Finally, five different Skyline
“Instrument Method templates” were generated, including all specific
MRM transition information: (1) Study9S_ABI_MichromMix_template.
sky (for 4000 QTRAP instruments), (2) Study9S_ABI5500_MichromMix_
template.sky (for QTRAP 5500 instrument), (3) Study9S_Thermo_
MichromMix_template.sky, (4) Study9S_Waters_MichromMix_template.
sky, and v) Study9S_Agilent_MichromMix_template.sky. All Skyline
Method templates were uploaded onto Panorama (panoramaweb.org,
additional details below) and further details can be viewed in supple-
mental Table S1. Skyline Instrument Method templates were distributed
to all sites and were used to export a transition list that could be directly
imported into the mass spectrometer vendor method set-up (for de-
tailed description see supplementary Methods).
Reversed Phase Nanoflow High Performance Liquid Chromatogra-
phy (nanoHPLC)—Peptide mixtures were separated by on-line re-
versed phase nanoHPLC systems equipped with autosamplers: two
NanoLC-1D Plus systems, seven NanoLC-2D systems and two Nano-
LC_Ultra systems, one NanoLC_Ultra 1D Plus and one NanoLC_Ultra
2D Plus from Eksigent Technologies (Dublin, CA); one Ultimate 3000
system from Dionex (Sunnyvale, CA); one nanoAquity system (Wa-
ters, Milford, MA); and two 1100 series systems (Agilent, Santa Clara,
CA). PicoFrit® (New Objective, Woburn, MA) columns, 75 m ID x 120
mm, 10 m ID tip, were self-packed with ReproSil-Pur C18-AQ (3 m
particle size and 120 Å pore size) at each of the sites. Separations
were performed at mobile phase flow rates of 300 nL/min using 0.1%
(v/v) formic acid in water (mobile phase A) and 90% (v/v) acetonitrile
with 0.1% (v/v) formic acid (mobile phase B). One microliter injections
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of the peptide digestion mixture were separated using a gradient of
3–15% B in 3 min, 15–35% B in 34 min, 35–90% B in 3 min, and at
90% B for 4 min. Each site, except the Agilent ChipCube-LC instru-
ments, acquired sample data with a PicoFrit/direct injection HPLC
hardware configuration set-up. Details including plumbing configura-
tions and autosampler injection routines are described in the SOP
(see supplementary Methods and supplemental Table S2).
Mass Spectrometer Operating Parameters—General instrument
operating parameters were kept as uniform as possible across the
different MS platforms, except where noted in the individual sections
below (additional details found in SOP, supplementary Methods and
supplemental Table S2A). All MRM transitions are listed in supple-
mental Table S1. A total of 115 MRM transitions were monitored
during an individual sample analysis with Q1 and Q3 set to unit
resolution and the dwell time set to 10 msec for each transition.
ABI 4000 QTRAP/QTRAP 5500 Mass Spectrometer—Nine 4000
QTRAP hybrid triple quadrupole/linear ion trap mass spectrometers
(AB Sciex, Foster City, CA) located at different sites were used to
acquire MRM-MS data for this study. Ion spray voltages of 2200 
200 V, curtain gas 20, nebulizer gas (GS1) 5  2, and interface heater
temperature (IHT) 150 °C were used. Declustering potential (DP), and
collision energy (CE) were calculated in Skyline using the following
regression equations: DP  0.0729*m/z  31.117 and CE 
0.0431*m/z  4.7556 (from personal communication with Dr. Jeffrey
Whiteaker). Interscan delays were set to 5 msec and cycle times were
1.73 s. The QTRAP 5500 instrument was operated in a similar manner
(for differences see supplemental Table S2A, and supplementary
Methods). The following CE linear equations were used: CE 
(0.036*m/z  8.857) for z  2 and CE  (0.0544*m/z  2.41) for z 
3. For the QTRAP 5500 an interscan delay of 3 msec was used for all
transitions, resulting in slightly shorter cycle times of 1.495 s.
ThermoFisher TSQ Quantum Ultra/TSQ Vantage Mass Spectrom-
eter—One TSQ Quantum Ultra triple quadrupole mass spectrometer
(ThermoFisher Scientific, San Jose, CA) was used to acquire MRM
data for this study. Representative instrument operating parameters
for the TSQ Quantum Ultra included spray voltage of 2300 V, capillary
offset voltage of 35 V, and capillary temperature of 275 °C. Tube lens
voltages used for all peptides, which were based on values generated
during the automatic tuning and calibration process, were not indi-
vidually optimized. The collision energy (CE) was calculated with
Skyline for all individual precursors using the CE linear equation CE
0.034*m/z  3.314 for doubly-charged peptides. Collision cell argon
gas pressure was 1.5 mTorr, scan width of 0.002 m/z, (for more
details see supplemental Table S2A) and the total cycle time was
1.48 s. The TSQ Vantage instrument was operated in a similar man-
ner: spray voltage of 1300 V, and capillary temperature of 210 °C. Q1
and Q3 unit resolution of 0.7 FWHM, Q2 Argon gas pressure of 1.5
mTorr, scan width of 0.005 m/z, and total cycle time of 1.32 s. TSQ
Vantage 2.0.0 and Xcalibur 2.0.7 SP1 operating software were used.
On the TSQ Vantage, the Skimmer Offset and Tube Lens were re-
placed by the S-Lens (for typical S-Lens settings see Supplementary
Methods).
Waters Xevo TQ Mass Spectrometer—One Waters Xevo TQ triple
quadrupole mass spectrometer (Milford, MA) was used to acquire
MRM data for this study. The collision energy (CE) for Waters instru-
ments was calculated within Skyline using the linear equation CE 
0.034*m/z  3.314. In the tune page the capillary voltage was set to
2.2 kV, the collision gas to 4 ml/min, and the Cone Voltage to 37 V.
MS Inter-scan time and the Inter-channel Delay were both set to 3.5
msec with a total cycle time of 1.55 s. MassLynx version 4.1 SCM725
was used.
Agilent ChipCube Mass Spectrometer—One Agilent 6410 and one
6460 triple quadrupole mass spectrometers (Santa Clara, CA) cou-
pled to ChipCube interfaces were used to acquire MRM data. The CE
for Agilent instruments was calculated in Skyline using the linear
equation CE  0.036*m/z  4.8. The ESI Voltage was 1750 V with a
gas flow of 2.5 L/min, source temperature of 325 °C and Fragmentor
Voltage of 125 V. The total cycle time was 1.485 s. MassHunter
version 4.01 was used.
System Suitability LC-MRM-MS Data Acquisition—Mass spectro-
metric data were acquired for (1) a column conditioning study, com-
prised of ten subsequent HPLC-MS-MRM analyses of 50 fmol/l of
the 6ProteinMix-QC to assess how rapidly a newly packed reversed
phase nanoHPLC column stabilizes and conditions, and (2) a
“Phase I” Study comprised of ten subsequent HPLC-MS-MRM anal-
yses of 50 fmol/l of the 6ProteinMix-QC to assess system suitability
metrics. Chromatographic carry-over effects were assessed in three
blank injections which followed the Phase I runs. Chromatographic
hardware setup for Phase I at all sites was required to be a PicoFrit/
direct injection configuration with a 1 l loop, except for the Agilent
instruments, which used a ChipCube interface. Further study details,
such as sample setup, sample and file naming nomenclature etc. are
described in the accompanying SOP (supplementary Methods).
Concentration Curve for 10 Analyte Peptides: LC-MRM-MS Data
Acquisition—To evaluate the relationship between system suitability
performance and instrument sensitivity in a quantitative assay, the
SSP was used in the context of a larger study in which 125 analyte
peptides were monitored by a scheduled MRM-MS method at a
number of the participating sites. A nine-point calibration curve was
prepared in human K2EDTA plasma that had been delipidated and
depleted of the high abundant proteins using the Multiple Affinity
Removal System (MARS-14, Agilent) by PPD Biomarker Discovery
Sciences (Menlo Park, CA). The plasma was denatured, reduced and
alkylated, digested with Lys-C and trypsin and desalted according to
a standard operating procedure. The depleted plasma digest was
spiked with a total of 125 synthetic 12C/14N peptides and the corre-
sponding 13C/15N-isotopically labeled internal standard peptides. The
standard curve consisted of the on-column concentration range from
1 amol/l to 100 fmol/l (with 8 concentration points prepared in
quadruplicate) prepared by serial dilutions in a 0.5 g/l background
of the depleted plasma digest and a constant concentration of 10
fmol/l of all isotopically labeled peptides. All sample preparations
were performed at a central location before distribution of samples to
selected sites.
Of the 125 peptides spiked into the depleted plasma digest, 115
represented potentially cancer relevant peptide targets and were
used in the context of a larger multiplexed study (30). The remaining
10 peptides, derived from seven target proteins (aprotinin: AGLCQT-
FVYGGCR; C-reactive protein: ESDTSYVSLK and GYSIFSYATK;
horseradish peroxidase: SSDLVALSGGHTFGK; leptin: INDISHTQSV-
SAK; myelin basic protein: HGFLPR and YLASASTMDHAR; myoglo-
bin: LFTGHPETLEK; and prostate specific antigen: LSEPAELTDAVK
and IVGGWECEK), had previously been well-characterized and as-
sayed in Addona et al. (21), and were used to assess the limits of
detection and quantification as related to SSP performance.
Timed-acquired multiplexed LC-MRM-MS was employed based
on the retention times of each peptide being monitored. Using the
isotopically labeled peptides, a series of six to seven unscheduled
LC-MRM-MS analyses were performed with each run represented by
a separate LC-MRM-MS method. Retention times of each peptide
were determined and used to generate a single scheduled method
using a 2-min retention time window. The SSP was applied before the
analysis of the standard curve samples using an unscheduled LC-
MRM-MSmethod to condition the column and assess instrument and
LC-performance over five replicate injections. To track the instrument
performance throughout the acquisition of the standard curve, the
6ProteinMix-QC was analyzed after every six to eight runs in the
sample queue.
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Data Analysis Platform - Skyline—Due to the demands of compar-
ing results from 12 laboratories using instruments from 4 different
vendors, we used the software application Skyline which allowed for
a common data analysis platform to be used across sites that fos-
tered sharing of data during acquisition as well as in final reports from
each laboratory. Native instrument data files were imported into Sky-
line using the ProteoWizard Data Access Library. Skyline stores the
data it needs from these files in a high-performance data cache file,
which simplified sharing data between laboratories during the acqui-
sition phase.
The MRM transitions for each peptide were integrated with Skyline
to generate ion current peak areas representing each of the fragment
ion signals. All data analysis and peak area integrations were initially
performed at each of the sites; however, all data sets were further
inspected at one central site for uniform data analysis and uniform
determination of outlier peaks. Processed MRM data, such as peak
areas, peak heights, chromatographic parameters, etc. were directly
exported from Skyline as customized report tables for further statis-
tical analyses (as .csv files). The Skyline report wizard was used to
create a uniform report template with specific data fields of interest.
These reports were then further processed with Excel, R and our own
cross-site validation tools to generate further statistical results and
graphics.
Supporting Data Analysis Software “Retention Time Viewer Pro-
gram” (RT-Viewer)—The Retention Time Viewer program is one ex-
ample of how exported Skyline reports were used for cross-site data
analysis (available for download at http://gibsonproteomics.org/
resources/rt-viewer). It was developed to easily visualize and trouble-
shoot chromatographic properties of identical samples analyzed be-
tween multiple laboratories or across all participating sites.
Statistical Methods—Data from MRM-MS experiments were pre-
processed and integrated in Skyline, and exported as customized
report tables in comma-separated value format (as .csv files). A
uniform processing and export template was used for all MS instru-
ments, resulting in output that was instrument independent. Only a
limited set of key fields in Skyline were used in the statistical calcu-
lations to ensure that special features unique to Skyline were not used
to keep the calculations free from unwarranted software depen-
dences. To this end, the following fields were extracted from Skyline:
sample name, peptide sequence, replicate name, retention time, area,
full-width-half-maximum (FWHM) peak width, fragment ion, precursor
charge and product m/z. These extracted fields were then processed
using custom developed code written in the R statistical program-
ming language (31).
The following calculations and analyses were performed with this
data.
● Determine Number of Transitions to Use for the Analysis—A
preliminary analysis was performed to evaluate whether the use of
three, four, or five transitions resulted in a more robust measure of the
various peptide parameters including retention time, peak width and
peak area, specifically focusing on peak area. The coefficient of
variation for peak area was very similar irrespective of how many
transitions were used (supplemental Fig. S1). Based on these results,
all five measured transitions have been retained for further analysis.
● Choose a Representative Subset of Peptides—The retention
time, peak area and peak width of the 22 targeted peptides were
monitored across different triple quadrupole instruments, sites and
HLPC systems to choose a robust subset. The peptides in this subset
were required to span the entire retention time range in a relatively
uniform fashion, and have a reasonably good and consistent re-
sponse. Based on the results displayed in supplemental Fig. S2 and
Supplemental Table S3, the nine peptides highlighted in red in Sup-
plemental Table S3 were selected and were used for subsequent
analyses for evaluation of system suitability.
● Combine Information From all Five Transitions for Each Peptide—
The retention time of the most intense transition was taken to repre-
sent the peptide retention time for that specific replicate. The maxi-
mum FWHM peak width over the 5 transitions was defined as the
peptide FWHM peak width, and the peak area for the peptides was
obtained by summing the peak areas for the 5 transitions.
● Normalized Peak Area—Not only do MS instruments from differ-
ent vendors provide different measured responses for a given peptide
in terms of peak area (or intensity), even identical instrumentation
from the same vendor provides varying responses. To account for this
arbitrary variation in peak area, and to render the measurements of
the same peptide comparable from site to site, we calculated the
normalized peak area for the best nine peptides. The peak area for
each of the 9 peptides was represented as a fraction of the total peak
area for the nine peptides, resulting in a normalized peak area ranging
between 0 and 1 for all peptides and all sites (supplemental Fig. S3).
● Chromatographic Resolution—The ability of chromatography to
separate peptides in time is represented by resolution. For a given
pair of peptides, resolution was calculated as the difference in reten-
tion time for the two peptides divided by the sum of the FWHM peak
widths for the peptides [Resolution (RT2-RT1)/(FWHM1FWHM2)].
In this study, peptides were sorted in order of increasing average
retention time (over all the sites), and resolution was calculated be-
tween prespecified adjacent pairs of peptides (supplemental Fig. S4).
● Peak Capacity—Peak Capacity was determined for each sample
acquisition replicate. First, the RT spread for the best 9 peptides was
calculated subtracting the RT of the first eluting peptide (for all sites
RT of peptide TAA) from the RT of the last eluting peptide (for all sites
RT of peptide FFV) (supplemental Fig. S5). Peak Capacity was then
calculated by dividing the determined retention time spread by aver-
age peak width at base line for best nine peptides [Peak Capacity 
[RT(FFV)  RT(TAA)]/(average peak width at base line for best nine
peptides) (32) (supplemental Table S4).
● Peak Tailing—Peak tailing was calculated as full peak width at
baseline divided by (factor 2 multiplied with front half width of the
peak), with front half width defined as “from the start of where the
peak elutes at baseline to the apex.” Peak tailing  AC/(2*AB), in
which AC is the width of the peak at baseline and AB is the front
half-width at baseline, (A: start eluting of peak at baseline, B: apex,
and C end eluting of peak at baseline (supplemental Fig. S6, supple-
mental Table S5).
● Retention Time Drift—The retention time drift is determined for
each peptide over the course of 10 replicate injections (RT drift 
RTmax  RTmin) (33) (Fig. 2A, Supplemental Table S6).
● Coefficient of Variation (CV)—CV values, calculated as the ratio of
the standard deviation to the mean, estimate variation for parameters
of interest including retention time, peak area, normalized peak area,
FWHM peak width, chromatographic resolution and peak capacity. In
addition, CV reports were generated directly out of Skyline for the
best nine peptides using a specific “CV results report” Skyline report
template (supplemental Table S7).
● Column Conditioning and Carryover—Ten replicate injections of
the 6ProteinMix-QC were made during the “column conditioning”
phase of this experiment and data were analyzed to determine the
optimal number of injections that resulted in achieving more stable
retention times, peak areas, peak widths, etc. (data shown in supple-
mental Fig. S7). Although there did not seem to be agreement across
sites on a precise number of injections that resulted in minimized
variances for each of the measured metrics, it was clear that the first
injection for most sites was the most variable, specifically in terms of
retention time.
For carryover analysis the peak area from the last three replicate
runs of the 6ProteinMix-QC, R08-R10 were compared with three
post-sample blank injections as regular and logarithmic plots, respec-
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tively (supplemental Fig. S8). For more specific carryover calculations,
for each peptide the peak area of each blank, Bl-1, Bl-2, and Bl-3 was
divided by the mean of the peak area of sample replicates R8-R10
(supplemental Table S8). Most peptides appeared to have a similar
extent of carryover at a given site with a few exceptions. The absolute
intensity of the carryover correlated to the absolute intensity of the
peptides in the preceding injections, in that more intense peptides
displayed a larger signal in the blanks. Each successive blank de-
creased the overall signal from each peptide with the peak areas of
the third replicate equaling about 0.1% of the peak areas of the 50
fmol injection.
Graphical Methods—Data from MRM experiments exported from
Skyline and analyzed using the custom R code described above are
further explored using a variety of plots, also generated using the R
statistical computing environment (http://www.R-project.org) (29), spe-
cifically the Lattice Graphics package (34). Comprehensive plots were
made to analyze not only the overall statistics such as CV, but also
understand more detailed variation of the LC and MS parameters and
measurements from replicate to replicate, between sites and across
peptides. See Fig. 3 and supplemental Figs. S4–S6.
Calculation of LOD for 10 Peptides From Nine-point Curve—Limits
of detection for 10 peptides from a 9-point response curve in 0.5
g/l plasma were determined as previously described (21).
Assessment of Pass/Fail Metrics for System Suitability MRM-MS
Assays—The following metrics were used for assessing LC-MRM-MS
instrument performance: i.) RT Drift, ii.) Standard Deviation of RT, iii.)
CV of FWHM, and iv.) CV of Peak Area. The median value for each
peptide across 14 of the 15 instruments participating in this study
were determined and reported along with the range of values. One of
the 15 instruments was excluded due to HPLC-related issues that
caused many values to be inflated compared with all other sites.
Data Availability on Panorama—All data have been uploaded to
PanoramaWeb, an open-access web site, hosted by the MacCoss lab
at the University of Washington, running on the open-source Panorama
software (35) created as part of the LabKey Server (36). Data can be
found at http://proteome.gs.washington.edu/software/panorama/
abbatiello_study9s.html.
RESULTS
Initial Analysis of the Protein Digest Standard: Selection of
Peptides, Transitions, and Performance Metrics to Monitor—
Our first task was to select the appropriate tryptic peptides to
monitor from the six protein digest mixture and identify met-
rics for assessing reproducibility and performance integrity of
the nanoflow HPLC-MRM-MS systems during routine analy-
sis at 11 sites comprising 15 individual systems. Initial exper-
iments conducted at a subset of the laboratories generated
preliminary qualitative data from which 22 peptides (23 pre-
cursors, one peptide was monitored using two precursors)
were selected for monitoring using 5 transitions each, facili-
tated through the use of Skyline (Fig. 1). The LC-MRM-MS
method was designed to be analyzed in a retention time
independent manner (not time-targeted), so that shifts in pep-
tide elution would be observed. Each site acquired 10 repli-
cate injections of 50 fmol (on column) of the SS sample to
condition the freshly packed Picofrit columns, followed by 10
additional injections for metric assessment. Lastly, three in-
jections of “null matrix” (mobile phase A, 0.1% formic acid)
were acquired to determine the extent of carryover. Although
22 peptides were monitored in the final method, we illustrate
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FIG. 1. Workflow for the development, evaluation and use of a
system suitability protocol (SSP) for system performance. A,
scheme of the method development process for picking peptides and
transitions from a predefined sample, including generation of spectral
libraries, generation of vendor-specific transition lists, data process-
ing, and report generation in Skyline. Exported Skyline data reports
were further analyzed to select the nine most appropriate peptides
(based on criteria outlined in text) for use in the SSP for all sites. B,
use of the SSP for evaluating system performance. The final nine
peptides are acquired and the data analyzed in Skyline, from which
the data metrics (peak area CV, normalized peak area CV, RT drift, RT
standard deviation, and FWHM CV) can be directly exported in a
report format to observe Pass/Fail status.
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key results using nine peptides spanning a range of electro-
spray response, all of which were detected equally well
across all instruments and that had retention times spanning
the entire gradient (supplemental Figs. S1, S2, S9 and Sup-
plemental Table S3). The workflow representing peptide se-
lection and method development across the various instru-
ment platforms is shown in Fig. 1A. The goal of developing a
SSP for its use in multiple laboratories was to define and
implement Pass/Fail criteria for evaluating whether or not a
LC-MRM-MS instrumental configuration is suitable for per-
forming a preconfigured assay. Accordingly, applying the SSP
would prompt a site to proceed with the assay if the SSP
criteria were passed or pause and troubleshoot the LC-
MRM-MS system if it failed to meet all or part of the assess-
ment (Fig. 1B). The specific parameters that we selected to
monitor and develop pass/fail metrics and the rationale for
their selection are described below.
Retention Time Variability—Retention time (RT) stability is
one of the more important criteria for multiplexed MRM-MS-
based assays. With modern triple quadrupole instruments it is
quite straightforward to monitor ca. 20 different peptides in a
1 s scan cycle using three transitions/peptide (i.e. 3 MRM
transitions  20 peptides, with 10 msec dwell time/transition
and 5 msec interscan delay for each transition cycle time of
0.9 s). This data acquisition rate is compatible with typical
nanoflow chromatographic peak widths and the need to sam-
ple multiple instances across a peak. However, it is both
possible and desirable to configure assays to monitor much
larger numbers of peptides in a single LC-MRM-MS analysis,
for example 100 analyte peptides and 100 corresponding
stable isotope-labeled internal peptides with three transitions
monitored each, for a 200-plex assay. To achieve this multi-
plex level requires that the MS instrument is programmed to
detect only selected peptides during predefined retention
time windows. This is generically referred to as “scheduling”
and has been implemented by all vendors of triple quadrupole
instruments. Scheduled MRM can greatly increase the num-
ber of analytes that can be targeted and detected in a single
LC-MRM-MS analysis. However, for it to work as desired the
retention time stability is crucial and the target peptides must
elute in the predefined RT windows, otherwise compromised
signal or no signal will be detected. Therefore, assessing RT
variability is an important parameter to define and monitor in
the SSP.
The average RT and its variability over ten injections were
calculated to determine if there were large shifts in RT of
individual peptides over the course of the experiment, and if
the variability in the RT was random or systematic. The results
are visualized in Fig. 2. A peptide’s RT drift was defined as the
range of RTs from a given site over the course of 10 replicate
injections of the SS standard (RT drift  RTmax  RTmin, for a
given peptide at an individual site). In Fig. 2A the RT drift
ranges for 9 of the monitored peptides is shown for each of
the participating sites, and are grouped according to the
model of nanoHPLC system used. Ideally the observed RT
drift at an individual site should be minimal; however, certain
sites experienced RT drift of up to 1 min for several peptides
during the 10 replicate injections.
The RT drift of each peptide was also evaluated within and
across sites for the 10 replicate injections using “Retention
Time Viewer” (RTV) software (http://gibsonproteomics.org/
resources/rt-viewer). The results for one of the peptides,
CAVVDVPFGGAK (CAV; from glutamate dehydrogenase) for
each technical replicate at eight of the sites are shown in Fig.
2B (see also supplemental Fig. S10 and supplemental Table
S6). RT drift at many of the sites was random (e.g. Sites 6, 8,
9, and 10), whereas more systematic drift toward longer re-
tention was evident at other locations (e.g. Sites 12, 14, and
15), possibly indicating slightly decreasing flow rates or a
systematic change in mobile phase composition over time for
these systems. In addition, for assessment of RT reproduc-
ibility at a single site, Skyline provided a peptide replicate
view, allowing the RTs of each transition for a given peptide
(CAV in this example, Fig. 2C) to be compared across repli-
cate injections. This view was critical to the instrument oper-
ators because it quickly indicated gross shifts in RT, which
can be a symptom of column degradation or ambient tem-
perature fluctuations, and allowed for rapid troubleshooting of
the LC-MRM-MS system. The total spread in absolute RT
between sites for this peptide was 5 min and was ex-
plained by differences in capillary length used to plumb the
nanoflow HPLC (supplemental Table S2B), and was also
attributed to differences in the self-packed columns used at
each site (target length, 12 cm  1 cm).
Raw Peak Area and Normalized Peak Area—To assess MS
detector response reproducibility, raw peak areas were mon-
itored for each peptide over replicate injections. Due to the
variety of triple quadrupole (TQ) MS instruments employed in
this study and the difficulty in comparing MS detector inten-
sities across platforms, the raw peak area values for each
peptide were normalized to the total peak area detected for
the 9 peptides shown (Fig. 3 and supplemental Fig. S3A and
S3B) in each separate LC-MRM-MS run, as described in the
Methods section. The observed normalized peak areas for the
majority of peptides varied over a narrow range (less than
3-fold) across sites and were largely independent of differ-
ences in instrument configurations across sites (Fig. 3A). In
general, the CV of the normalized peak areas was0.15 for all
sites, except for a few later eluting peptides (DDG, VGP, FFV)
that had somewhat higher CVs. The sites that observed higher
normalized peak area CVs for later eluting peptides also had
more variable raw peak areas for these peptides, in some
cases related to electrospray stability (supplemental Fig. S11)
as well as lower mean peak areas (Site 5, Fig. 3A). The median
CV of normalized peak area for 14 of the instruments ranged
from 0.04–0.08 across the 9 peptides, with the maximum CV
of 0.36 for peptide FFV, which tended to have a large range of
peak areas across instruments (Table I). Site 9 (purple symbol,
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FIG. 2. Evaluation of retention time
stability from the SSP. A, RT drift ob-
served for the 9 peptides on each of the
15 instrument platforms, grouped by LC
manufacturer. Peptides are sorted in or-
der of increasing retention time drift at
each site. B, RT Viewer display of the
injection-to-injection RT drift for peptide
CAV (CAVVDVPFGGAK from glutamate
dehydrogenase) at 14 selected sites.
Sites 12, 14, and 15 show the largest
drift in RT whereas sites 3, 8 and 10
show the smallest. Site 11 is not dis-
played as results were off scale due to
problems with flow calibration. C, Sky-
line display of injection-to-injection vari-
ability in RT for one peptide at Site 10.
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Fig. 3A), consistently had the lowest normalized peak area
CVs for each of the peptides monitored despite using an
older generation system, the AB Sciex 4000 QTRAP. Al-
though certain peptides exhibited a wider and higher range
of CVs appearing to correlate with greater variation in their
mean normalized peaks areas across sites (e.g. compare
peptides LVN with peptide FFV, and early eluting peptides
TAA and DGG with peptides eluting in the middle of the
gradient), most of the variation observed in normalized peak
area and peak width did not appear to be site specific. We
investigated this phenomenon further and found that the
more hydrophobic peptides YLGYLEQLLR, VGPLLACLLGR
and FFVAPFPEVFGK (YLG, VGP, and FFV, respectively)
exhibited decreasing raw peak area with increasing storage
time in the autosampler (4 °C at 50 fmol/l in 0.1% formic
acid). Given that these peptides were at low concentration
in a relatively noncomplex sample matrix it is likely that they
adsorbed to either the sample vial walls or, in one case, to
the coated metal autosampler needle during sample aspi-
ration. Monitoring the intensities of these peptides over
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TABLE I
The median and range of SS metrics is shown for the 9 SS peptides for 14 instruments. Median and range values were determined from 10
replicate injections at each site
TAA GFC DGG VLD CAV LVN DDG VGP FFV
RT drift (min) 0.25 0.30 0.26 0.34 0.37 0.42 0.45 0.44 0.50
0.09–0.60 0.10–0.72 0.12–0.72 0.12–0.89 0.15–0.89 0.15–1.04 0.14–1.15 0.17–1.01 0.20–0.91
Std Dev of RT (min) 0.08 0.10 0.09 0.11 0.12 0.12 0.13 0.14 0.14
0.03–0.19 0.03–0.22 0.03–0.23 0.04–0.28 0.05–0.26 0.05–0.36 0.04–0.43 0.05–0.36 0.06–0.30
CV of FWHM 0.07 0.06 0.08 0.06 0.05 0.07 0.07 0.06 0.06
0–0.19 0–0.14 0.02–0.12 0.03–0.19 0.03–0.12 0–0.24 0.02–0.16 0.02–0.22 0.03–0.20
CV of peak area 0.10 0.08 0.07 0.07 0.09 0.08 0.08 0.11 0.10
0.04–0.27 0.04–0.28 0.04–0.28 0.03–0.25 0.03–0.26 0.04–0.25 0.03–0.23 0.04–0.26 0.04–0.36
Quantitative Assessment of Instrument Performance
Molecular & Cellular Proteomics 12.9 2631
subsequent injections indicated an issue through decreas-
ing or nonexistent signal.
The normalized peak area for replicate injections, plotted
individually for each peptide by site is shown in Fig. 3B. This
view of the data facilitates observation of site-specific trends
such as systematic variation in normalized peak area as well
as anomalies occurring in any single replicate. For example,
peptide VLDALDSIK (VLD; carbonic anhydrase) decreased
2-fold in injection number 2 at Site 5 relative to all other
measurements for this peptide at that site (Fig. 3B) resulting
in a higher CV for this peptide. On further analysis of the
data, the observed decrease in normalized peak area for
this injection was due to unstable electrospray whereas the
peptide was eluting, which was also the cause for the sites
that had CVs higher than 0.15 for peptides TAA and DGG.
Additional examples of performance deviation are detailed
below. Although normalized peak area was employed in this
study for cross-site comparison, we recommend simply
using raw peak area for single LC-MRM-MS configuration
evaluation since this metric is a quantitative output of Sky-
line software, which allows easy assessment of system
performance (Fig. 4).
Peak Width (FWHM)—The peak width at FWHM metric
allows comparison of a fundamental aspect of chromatogra-
phy over time on one instrument and between individual sites.
Overall, peptide peak widths within a site were highly repro-
ducible with CVs generally 0.2 and often 0.15 in which the
FWHM values for individual peptides varied between sites
from 0.1 min to 0.3 min. Later eluting peptides exhibited
somewhat larger variation in peak width across sites suggest-
ing a gradient-dependent effect. The individual FWHM values
for each replicate are plotted in supplemental Fig. S12, where
the increasing range of FWHM values between sites for later
eluting peptides is more apparent. The four sites with different
HPLCs [supplemental Fig. S12, Sites 3 (Waters nanoAcquity),
4 (Eksigent Ultra 1D), 5 (Eksigent Ultra 2D), and 15 (Dionex
U-3000)] did not stand out from the laboratories using Eksi-
gent 1D Plus and 2D nanoHPLCs. This indicates that the
major sources of variability observed were more likely due to
variations in how the LCs were plumbed (supplemental Table
S2B), and dissimilarities in the self-packed columns rather
than major differences in performance between HPLCs from
different vendors or separate models of HPLC from the same
vendor.
Chromatographic Resolution, Peak Capacity, and Peak Tail-
ing—Chromatographic resolution (Rs) was calculated for ad-
jacent eluting peptides to observe the variation in this param-
eter during column conditioning and over the 10 subsequent
replicate injections (supplemental Fig. S4). Although some
sites exhibited more consistent Rs values over the 10 injec-
tions, the trends observed between the sites were very similar
in that Rs values did not change substantially with peptides
maintaining elution order and spacing. Peaks exhibiting the
largest variation in Rs also happened to have the lowest
calculated Rs values at each site indicating small changes in
closely eluting peptides. Eleven of the 15 sites maintained
CVs less than 0.15 for almost all peaks. The remaining 2 sites
with CVs above 0.15 (Sites 3 and 6) also had slightly more
variable FWHM values, which would affect Rs.
Peak capacity (nc) was evaluated to determine if the reten-
tion time span over which the peptides eluted changed during
the replicate injections, as well as to compare across sites
(Supplemental Fig. S5, supplemental Table S4). Although the
peak capacity values ranged from 40 to 75 between the
various sites, the reproducibility within each site was excellent
with CVs  0.075. This divergence in peak capacity values
across the sites may be explained by differences in the cap-
illary tubing used to plumb the nanoHPLC, the dissimilar
column length, or the efficiency of the nanoHPLC pumps in
delivering the proper gradient conditions.
Chromatographic peak shape was evaluated by calculating
the Peak Tailing Factor (PTF) in the Retention Time Viewer
Program. All sites observed PTF very close to 1 for every
peptide monitored, which indicated overall suitable peak
shape (supplemental Fig. S6, supplemental Table S5).
Software Tools for SSP Development and Evaluation—A
critical requirement of implementing a LC-MRM-MS SSP is
the capability to rapidly determine if the instrument platform is
performing within specifications. We used several features in
Skyline to view LC-MRM-MS data from replicate injections
that enabled quick assessment of reproducibility (Fig. 4 and
supplemental Fig. S13). First, peptides were sorted in order of
their RTs and the mean peak areas for the 10 replicates were
plotted with error bars representing one standard deviation
(Fig. 4A). Second, changing the view to plot peak area CV on
the y axis allowed for a quick evaluation of the overall repro-
ducibility of the injections for all peptides, in which the goal
was for the CV to be as low as possible and less than 0.2 (Fig.
4B). Third, a replicate view allowed for inspection of the total
raw peak area (summed from all 5 transitions monitored per
peptide, in this case, TAA, Fig. 4C) for each replicate injection.
In cases in which unusually large CVs were observed it was
possible to quickly determine which injection was the outlier
(Fig. 5). Using these Skyline tools allowed operators to quickly
assess the quality of data over replicate injections of the SS
standard and determine whether the system was performing
normally. If irreproducibility was observed, then immediate
troubleshooting of the system was performed to identify and
rectify the problem. Finally, all SS sample runs generated
during a given timeframe were saved into a Skyline file to track
system performance over time.
The RTV program provided additional tools to quickly
assess chromatographic behavior by comparing across
multiple sites or instruments (supplemental Fig. S14). RTV is
an interactive, graphical Java program that imports a set of
Skyline reports, one per site. The program visualizes reten-
tion times of peptides across the sites for either all 10 HPLC
replicate runs or a subset of them. Features can be visual-
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ized for all sites at the same time or for a subgroup of
selected sites. For any single peptide, chromatographic
information similar to what Skyline displays for a single site
in the Retention Time Replicate chart can now also be easily
compared among many sites using the RTV program includ-
ing features, such as peptide retention time, start and stop
elution times, retention time stability or drift over sample
replicates, peak width (FWHM), peak tailing, etc. Average
values of all chromatographic properties over 10 replicate
HPLC runs were automatically calculated and displayed for
each CPTAC site, and all chromatographic data can be
exported as tabulated text.
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FIG. 4. Skyline tools developed for
rapid assessment of system suitability
performance at a single site. Panel A:
average peak area across 10 injections
for each of the original 22 peptides mon-
itored in the SSP (error bars represent 1
standard deviation). Peptides are sorted
in order of retention time with retention
time shown in the x axis. Panel B: CV of
the peak areas for each peptide across
10 injections. Panel C: view of results for
the raw peak area observed for peptide
TAA for 10 replicate injections; each
color representing the signal from the
individual transitions.
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FIG. 5. Before and After Plots of SSP Data from Individual Sites with System Performance Problems. Panel A: data from two SSP peptides
(CAVVDVPFGGAK and VGPLLACLLGR) that exhibited large retention time shifts (in blue), before room temperature stabilization at Site 10. When
the sample was re-run, the “after” retention time shifts, shown in green, are more representative of the retention time variability observed at other
sites. Panel B: unusually wide FWHM for peptide VLDALDSIK at Site 5, indicating a problem with the HPLC plumbing. After the connections were
fixed, Site 5 obtained narrower FWHM more typical of the other sites. Panel C: before and after view of the Peak Area view in Skyline for Site 4.
The last 5 peptides of the SS sample showed very low signal as compared with the other sites involved in the study. When Site 4 re-calibrated the
flow meter on their organic solvent pump, the peak areas for the later eluting peptides increased and were observed to be more similar to the other
sites. PanelD: same data from Site 4 as in PanelC but using the Peak Area CV view in Skyline. The later eluting peptides all have elevated CV values
for Peak Area in the “before” case. When the system was fixed, all CVs dropped, but the effect was largest on the later eluting peptides.
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Use of the SSP to Recognize Out of Bounds Variability in
System Performance—During the course of this investigation,
there were incidents of hardware issues and/or environmental
conditions that resulted in dramatically shifting retention
times, irreproducible peak areas, and peak tailing that caused
excessively large CVs (0.2). The SSP was instrumental in
the early detection of these complications. Fig. 5 illustrates
three “before and after” examples of problems encountered at
various sites and their remedies. In the first example, during
initial SSP test acquisitions, site 10 experienced wildly shifting
retention times for all peptides during the ten replicate injec-
tions of the SS standard. For example, peptides CAVVDVPF-
GGAK and VGPLLACLLGR demonstrated RT ranges of 378 s
(6.3 min) and 364 s (6.1 min), respectively (Fig. 5A). This site
identified the potential source of the RT fluctuation to be
systematic changes in the ambient temperature of the labo-
ratory over the course of a 24 h period. Once the temperature
was stabilized, the site re-ran the sample and obtained a very
stable retention time range of 13 and 18 s for the same
peptides (0.2 and 0.3 min, Fig. 5A). Example 2 illustrates peak
tailing, which is another indication of suboptimal chromatog-
raphy. At one point during the course of this study, site 7
began to experience peak widths of 0.5 min FWHM,
whereas this site previously had peak widths of 0.25 min
FWHM or less as did all other sites in the study (Fig. 5B). On
closer inspection of their nanoHPLC hardware, adjustment of
the liquid junctions in the autosampler valve to reduce dead
volume resulted in the peak widths returning to 0.25 min
FWHM. Finally, example 3 illustrates a problem with the later
eluting peptides at Site 4 that the SSP uncovered (Figs. 5C
and 5D). The last six peptides detected in the gradient were
exhibiting lower than average peak areas, with correspond-
ingly high CVs for those peptides (Fig. 5D, top panel). On
measuring the flow rates from the two nanoflow pumps de-
livering mobile phases it was found that mobile phase B was
being delivered at a flow rate lower than expected, resulting in
inconsistent peptide detection during the latter part of the
gradient. After flow rate calibration, the peptides were more
reproducibly detected and their peak area CVs returned to
0.1 (Fig. 5D, bottom panel). Additional similar Skyline plots
are shown in supplemental Fig. S15. In each case shown,
report templates were developed in Skyline to output the CVs
of the following metrics: retention time, FWHM, total area and
normalized area (shown in supplemental Table S9) in a tabular
format.
Acceptable Range of Variability in SSP Metrics—The two
goals of our study were to develop a SSP and data analysis
toolkit for routine use on individual LC-MRM-MS platforms,
and to attempt to define the acceptable range of variation in
each of the MS and LC-based parameters selected as per-
formance metrics. The data described to this point were ac-
quired on LC-MRM-MS systems that were known to be func-
tioning properly and that produced data with variability of less
than 20% for the various parameters measured. Therefore we
believe that the observed ranges in variation of each of the
parameters monitored serves to define what well performing
nanoLC-MRM-MS platforms should be able to achieve during
routine peptide-based assays. Table I presents the interlabo-
ratory median and range for all metrics monitored during the
SSP study for each of the 9 final peptides. Although the
magnitude of each parameter (e.g. peak area, FWHM, reten-
tion time) may differ somewhat from the values shown de-
pending on the actual flow rate, column packing material, LC
plumbing and MS instrument used, the CVs of each of these
metrics should remain low (0.2 for single peptides and 
0.15 for median of all peptides measured) assuming the sys-
tem is in good operating condition. In fact, when assessing 14
“normally functioning” systems, the median CVs for peak area
and FWHM did not exceed 0.11 for any peptide. Inconsistent
performance at certain sites is evident in the maximum values
for FWHM and peak area shown in Table I.
Effect of System Variability on Limit of Detection in Quanti-
tative Assays—The SSP was incorporated into a quantitative
study designed to target 10 analyte peptides and their corre-
sponding 13C/15N analogs in depleted and digested plasma
(21) to determine if there was a relationship between any of
the SS metrics and limits of detection (LOD). As described
above SS replicates were acquired at 8 sites, followed by
generating a response curve for the 10 analyte peptides
spiked into depleted human plasma at concentration levels
ranging from 0.001 to 100 fmol/l. Additional LC-MRM-MS
analyses of the SS standard were interspersed between (ev-
ery 8–12 injections) and following acquisition of the response
curve data. The 4 main metrics for the SSP (peak area CV,
FWHM CV, retention time standard deviation and retention
time drift) were calculated for the 9 SS peptides and the
median generated for each site. These values were plotted
against the median LOD for the 10 target peptides monitored
in the response curve, during which the SS runs were inter-
spersed. We observed that, although the correlations deter-
mined across 8 individual sites were weak (supplemental Fig.
S16), the metric with the strongest correlation was peak area
CV. This is further illustrated when comparing the perform-
ance of several instrument platforms for the same quantitative
assay (Fig. 6). As the system suitability metrics, specifically
peak area, begin to deteriorate during the assay, it adversely
affects determination of LOD, resulting in higher LODs than
what could otherwise be achieved. In all cases, each site
passed the preassay SS metrics (at or below median values
shown in Table I). However, Site 9 displayed a dramatic
increase in peak area CVs in subsequent SS samples
throughout the quantitative assay, accompanied by a greatly
elevated LOD as compared with the other 4 sites. Further
investigation of Site 9’s data revealed a gradual decrease in
peak area for each injection, causing irreproducibility in peak
area, increased CV values and poorer overall sensitivity.
Longitudinal Assessment of SSP—An important benefit of
using a SSP is the tracking of system performance over
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extended periods of time, before and after changes to the
hardware (either LC or MS), acquisition software, prevent-
ative maintenance, or routine maintenance, such as clean-
ing of the MS source. Software such as Skyline facilitates
the capture and storage of SSP data and provides longitu-
dinal snapshots of system performance as a function of
time, use, and maintenance. An example of SSP performance
over the course of a 10–12 day experiment is shown supple-
mental Fig. S17, in which the SS sample was injected at least
every 8–10 h at each of two laboratories. The SSP is sensitive
enough to detect deteriorating system performance and shows
improvement after corrective actions (cleaning the MS source)
were taken at one site (Site 5), whereas system performance
was relatively stable at the other (Site 11). Associated SS
metrics are provided in supplemental Table S10.
DISCUSSION
Before initiation of a quantitative LC-SID-MRM-MS peptide
based study, it is important to confirm that the nanoHPLC and
mass spectrometer are optimized to achieve the performance
level expected to detect and quanify the analytes of interest.
Although individual labs may have their own set of standards
and methods through which this is accomplished, cross-
laboratory comparison of LC-SID-MRM-MS assays is difficult
unless the same sample and methods are used. In addition,
until a lab has become accustomed to running a SSP, it is
difficult to know what levels of variability to expect from a
particular nanoHPLC-MRM-MS system. Here we described
the development, assessment and application of a SSP for
nanoHPLC-MRM-MS peptide based studies. The SSP con-
sists of a defined SS standard sample, for which well char-
acterized performance metrics under defined operating con-
ditions were established, and the software tools necessary to
facilitate data extraction for swift assessment of instrument
platform performance. The SSP developed allows for rapid
and thorough analysis of raw data derived at an individual site
and for cross-site comparison between different vendor plat-
forms. Based on these analyses, we recommend target CVs
for raw peak area of 0.15, with 0.25 defined as the maximum
allowable peak area CV. Recommended CVs for FWHM can
be lower, at a target of 0.10 and a maximum of 0.25. Target RT
drift values should be0.5 min with a maximum of 1 min, and
RT standard deviation target of 0.15 min and maximum of 0.5
min. These recommendations are based on the performance
of a wide range of instruments and laboratories and serve to
define what well performing nanoHPLC-MRM-MS platforms
should be able to achieve before commencing a peptide-
based quantitative study. Inflation of these values, specifically
peak area CV was observed in the context of a quantitative
assay (“throughout assay” SSP, Fig. 6), over the span of 100’s
of injections, and is not uncommon. However, keeping these
metrics at or below the maximum recommended value will
improve the chances of maintaining the best assay sensitivity
possible. Implementation of a SSP at key points in an assay
(before method development, periodically during method de-
velopment and quantitative assay acquisition, and after any
HPLC or MS hardware has been replaced, cleaned or ad-
justed) enables monitoring of specific metrics that may influ-
ence the day to day and month to month performance repro-
ducibility of the LC-MRM-MS system, and ultimately impacts
the overall precision and sensitivity of the method.
The SSP we developed uses a nanoLC-MRM-MS method
that monitors 9 tryptic peptides from a commercially available
predigested, equimolar mixture of 6 bovine proteins. This
standard is inexpensive ($0.10/injection), readily available
and easily prepared with minimal sample handling. This
method has been transferred to 4 different vendor platforms in
11 different laboratories across a total of 15 individual instru-
ment configurations. All data were analyzed through Skyline
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FIG. 6. Correlation of Peak Area CV of SS peptides and LOD of
peptides from a quantitative SID-MRM-MS assay. Six sites ac-
quired a 9-point response curve to determine LOD of 10 target
peptides. The SSP was acquired at the beginning of the study and
periodically throughout the response curve. Panel A: peak area CV of
the SS peptides for all injections of the SS sample throughout the
study for each site. Panel B: plot of the calculated LOD of 8 out of the
10 peptides from the quantitative study. The two peptides from CRP
were not included as endogenous amounts were detected in the
blank plasma matrix and LODs could not be accurately determined.
Quantitative Assessment of Instrument Performance
2636 Molecular & Cellular Proteomics 12.9
and Retention Time Viewer, both of which are publicly avail-
able and vendor neutral software packages. Transition lists for
data acquisition as well as report templates are available
on-line for use with Skyline. The methods described for pep-
tide and fragment ion selection could readily be applied to any
mixture of peptides, with the reporting templates adjusted
accordingly. In selection of a SS sample, we recommend
choosing something similar to the analytes of interest and
stable for at least 1 week in the autosampler (4 °C). During the
course of this study, several of the hydrophobic peptides
monitored were found to decrease in intensity after 1 week at
4 °C and when stored at low (25 fmol/uL) concentrations in
aqueous conditions (3% acetonitrile/0.1% formic acid, data
not shown). Ideally, a SS sample would be as stable as the
analytes targeted in a quantitative assay, yet sensitive enough
to changes in the LC-MS system to indicate potential issues
that would influence sensitivity or reproducibility. From a
practical standpoint, it is convenient if the sample requires
minimal preparation before use and is made reproducibly so
batch-to-batch variability is much smaller than the variability
in instrument performance.
Our study has defined a number of factors that can ad-
versely affect both the precision and accuracy of quantifica-
tion in LC-SID-MRM-MS assays. During the course of this
study, it became apparent that the hardware configuration of
the nanoHPLC system and its fluidic connections had the
largest impact on overall system performance and reproduc-
ibility. Therefore, many of the metrics chosen for evaluation
are chromatography-based measures including RT, peak
width (FWHM), chromatographic resolution, column peak ca-
pacity, and peak tailing. RT reproducibility is a key factor
when developing an assay to target many (20) analytes and
their corresponding internal standards. For highly multiplexed
scheduled MRM-MS, the RT of each peak must be accom-
panied by a scheduling RT window, allowing for small shifts in
the RT over the course of many acquisitions. If there are large
shifts in the RT of peptides then the RT window in the sched-
uling software must be increased to accommodate the large
shifts in chromatography. Opening up the RT window reduces
the number of concurrent transitions that may be acquired
within a reasonable scan cycle time and using appropriate
dwell times (e.g. 10 msec). Furthermore, if the RT window is
set too narrow, peptide peaks may drift outside of the acqui-
sition window and no data or partial data will be collected. It
is for these reasons that RT stability is a key aspect in this
SSP. Although the data shown do not represent the RT shifts
that might be observed over hundreds of injections or large
sample loads, it does provide a baseline of performance that
can be used to compare subsequent RT drift.
Variability in peak area and width can also produce impre-
cise and inaccurate quantitative results in a LC-SID-MRM-MS
assay (20, 21). Stable isotope-labeled internal standard pep-
tides help to reduce the variable effects of chromatography
and ionization. However, they cannot compensate for low
signal-to-noise resulting from an autosampler malfunction or
from erratic signal due to electrospray instability or signal loss
due to a dirty ion source - factors that all adversely affect
achievable LOD and LOQ values. Such events often occur
after multiple (tens to hundreds) injections on the same nano-
column, causing residue build-up on the nanospray tip or ion
optics in the source, column degradation, or air in the au-
tosampler. Identification of recurring events such as these
becomes more feasible when actively monitoring for effects
on the chromatography or MS signal using an SSP. The most
influential factor on peak area and width in this study was
quality of the fluidic connections associated with the nano-
HPLC. Introduction of even a small void in an autosampler
valve or fitting may introduce 1–2 l of dead volume, which
translates to several minutes of delay when flowing at 300
nL/min. In addition, dead volumes also introduce new sources
of mixing that can cause chromatographic tailing and irrepro-
ducible peak shapes (illustrated in Fig. 5B). We demonstrated
that 15 individual LC-MRM-MS instrument platforms were
able to achieve very similar FWHM and normalized peak areas
for the same sample. These results provide a baseline for the
metrics evaluated that any lab can target when configuring
their own hardware and assessing its performance. Additional
metrics such as chromatographic resolution and peak ca-
pacity are useful ways to monitor both environmental con-
ditions (ambient temperature) and column life during the
course of an assay that may cause subtle deleterious per-
formance. Both parameters had very small variances over
10 replicate injections for the 15 instruments involved and
together with RT drift or FWHM variation, can provide in-
sight to column degradation.
Interestingly, our study revealed that the SSP performance
metrics obtained on previous generation triple quadrupole
mass spectrometers (i.e. 4000 QTRAP) were comparable to
newer instruments (i.e. QTRAP 5500). These results point to
an obvious conclusion: best performance is not guaranteed
by using the latest generation of instruments, but rather, by
optimizing each component of the platform. The weakest
component will often be the limiting factor in terms of overall
data quality.
Assessment and tracking of longitudinal system perform-
ance is another benefit of employing a SSP for LC-MRM-MS
instrumentation. The use of software with simple visual and
tabular data outputs, such as Skyline and Retention Time
Viewer, allow easy access to the history of system perform-
ance, and can even provide a tool for on-the-fly evaluation of
changes to the LC or MS hardware or acquisition parameters.
Further, data can be uploaded to PanoramaWeb for easy
access to and storage of system performance.
In conclusion, assessment of the performance and repro-
ducibility of nanoHPLCs and triple quadrupole platforms us-
ing a SSP before the start of a study, and periodically through-
out the course of a study will help ensure that the quality of
quantitative data generated is reliable and reproducible. Im-
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plementation of a SSP as a standard procedure as part of
targeted quantitative peptide-based MRM-MS assays en-
ables potential problems to be identified early and addressed.
We believe that a SSP should be incorporated into all LC-
MRM-MS studies, whether the focus of the study is biological
or clinical, to allow laboratories to easily monitor their own
instrumental performance and to understand and minimize
variables affecting assay data quality. Incorporation of a ro-
bust SSP will help to ensure that analyte quantification meas-
urements can be replicated with good precision within and
across laboratories, and should facilitate widespread use of
this technology by the basic biomedical and clinical laboratory
research communities.
Public Access to the Data—An ftp server at the National
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for initiating uploads and downloads of large data files. The
data associated with this manuscript may be found at http://
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study9s.html. Accessible information includes processed data
results.
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